KHC
The Kidney and Hypertension Center

AstraZeneca

# "Pacific" Clinical Trial

This is a Phase 3 study to assess the efficacy, safety, and tolerability of Baxdrostat on renal outcomes and cardiovascular events in CKD and Hypertension patients. The study will compare Baxdrostat in combination with Dapaglifozin, compared with Dapaglifozin alone.

Participants must be at least 18 years old with a diagnosis of CKD and Hypertension.

## Specific Inclusion Criteria

- eGFR between 30mL/min/1.73m$^2$ and 75mL/min/1.73m$^2$
- UACR between 30mg/g and 5000mg/g
- SBP greater than 130mmHg at screening and greater than 120mmHg at randomization (dosing visit)
- On a stable ACEi or ARB for at least 4 weeks before screening
- Serum Potassium between 3.0mmol/L and 4.8mmol/L at screening

## Prohibited and Exclusionary Meds

- Potassium-sparing diuretics
- MRAs or Aldosterone
- Strong CYP3A4 inducers
- SGLT2i other than Dapagliflozin that is supplied by Astra Zeneca including Phlorizin
- Long term NSAIDS should be avoided (occasional use ok)
- Treatment with potassium supplements is not prohibited if as deemed by the Investigator, in order to keep subject from becoming hypokalemic

**1-833-24RENAL**
**khccares.com**